Randomized phase II trial of inhaled budesonide versus placebo in high-risk individuals with CT screen-detected lung nodules

Cancer Prevention Research

Volumn 4, Issue 1, 2011, Pages 34-42

  Veronesi, Giulia ^a   Szabo, Eva ^b   DeCensi, Andrea ^a,c   Guerrieri Gonzaga, Aliana ^a   Bellomi, Massimo ^a,d   Radice, Davide ^a   Ferretti, Stefania ^a   Pelosi, Giuseppe ^a,d   Lazzeroni, Matteo ^a,e   Serrano, Davide ^a   Lippman, Scott M ^f   Spaggiari, Lorenzo ^a   Nardi Pantoli, Angela ^a   Harari, Sergio ^g   Varricchio, Clara ^a   Bonanni, Bernardo ^a  

^a EUROPEAN INSTITUTE OF ONCOLOGY   (Italy)

^b NATIONAL CANCER INSTITUTE   (United States)

^c GALLIERA HOSPITAL   (Italy)

^d UNIVERSITY OF MILAN   (Italy)

^e SAPIENZA UNIVERSITY OF ROME   (Italy)

^f UNIVERSITY OF TEXAS MD ANDERSON CANCER CENTER   (United States)

^g San Giuseppe Hospital   (Italy)

Author keywords

[No Author keywords available]

Indexed keywords

BUDESONIDE; PLACEBO;

ADULT; AGED; ARTICLE; COMPUTER ASSISTED TOMOGRAPHY; DOUBLE BLIND PROCEDURE; DRUG EFFECT; DRUG RESPONSE; DRUG TOLERANCE; FEMALE; HIGH RISK PATIENT; HUMAN; HYDROCORTISONE BLOOD LEVEL; LUNG NODULE; MAJOR CLINICAL STUDY; MALE; PHASE 2 CLINICAL TRIAL; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; SIDE EFFECT; SMOKING; TASTE DISORDER; TREATMENT OUTCOME; VOICE CHANGE;

ADMINISTRATION, INHALATION; AGED; ANTI-INFLAMMATORY AGENTS; BUDESONIDE; DOUBLE-BLIND METHOD; ENDPOINT DETERMINATION; FEMALE; HUMANS; LUNG NEOPLASMS; MALE; MIDDLE AGED; MULTIPLE PULMONARY NODULES; PLACEBOS; PROGNOSIS; RESEARCH DESIGN; RESPIRATORY FUNCTION TESTS; TOMOGRAPHY, X-RAY COMPUTED;

EID: 78650847149     PISSN: 19406207     EISSN: 19406215     Source Type: Journal    
DOI: 10.1158/1940-6207.CAPR-10-0182     Document Type: Article

References (38)

1. Jemal A, Thomas A, Murray T, Thun M. Cancer statistics, 2002. CA Cancer J Clin 2002;52:23-47.
2. Horner MJ, Ries LA, Krapcho M, Neyman N, Aminou R, Howlader N, , et al. SEER Cancer Statistics Review, 1975-2006. Bethesda, MD: National Cancer Institute; 2009.
3. Enstrom JE, Heath CW Jr. Smoking cessation and mortality trends among 118,000 Californians, 1960-1997. Epidemiology 1999;10:500-12.
4. Tickle JJ, Sargent JD, Dalton MA, Beach ML, Heatherton TF. Favourite movie stars, their tobacco use in contemporary movies, and its association with adolescent smoking. Tob Control 2001;10:16-22.
5. King C III, Siegel M. The Master Settlement Agreement with the tobacco industry and cigarette advertising in magazines. N Engl J Med 2001;345:504-11. (Pubitemid 32758503)
6. Keith RL. Chemoprevention of lung cancer. Proc Am Thorac Soc 2009;6:187-93.
7. Lee JS, Lippman SM, Benner SE, Lee JJ, Ro JY, Lukeman JM, et al. Randomized placebo-controlled trial of isotretinoin in chemoprevention of bronchial squamous metaplasia. J Clin Oncol 1994;12:937-45.
8. Estensen RD, Jordan MM, Wiedmann TS, Galbraith AR, Steele VE, Wattenberg LW. Effect of chemopreventive agents on separate stages of progression of benzo[alpha]pyrene induced lung tumors in A/J mice. Carcinogenesis 2004;25:197-201.
9. Pereira MA, Li Y, Gunning WT, Kramer PM, Al Yaqoub F, Lubet RA, et al. Prevention of mouse lung tumors by budesonide and its modulation of biomarkers. Carcinogenesis 2002;23:1185-92.
10. Wattenberg LW, Wiedmann TS, Estensen RD, Zimmerman CL, Galbraith AR, Steele VE, et al. Chemoprevention of pulmonary carcinogenesis by brief exposures to aerosolized budesonide or beclomethasone dipropionate and by the combination of aerosolized budesonide and dietary myo-inositol. Carcinogenesis 2000;21:179-82.
11. Parimon T, Chien JW, Bryson CL, McDonell MB, Udris EM, Au DH. Inhaled corticosteroids and risk of lung cancer among patients with chronic obstructive pulmonary disease. Am J Respir Crit Care Med 2007;175:712-9.
12. Lam S, leRiche JC, McWilliams A, MacAulay C, Dyachkova Y, Szabo E, et al. A randomized phase IIb trial of Pulmicort Turbuhaler (budesonide) in people with dysplasia of the bronchial epithelium. Clin Cancer Res 2004;10:6502-11.
13. van den Berg RM, Teertstra HJ, van ZN, van TH, Visser C, Pasic A, et al. CT detected indeterminate pulmonary nodules in a chemoprevention trial of fluticasone. Lung Cancer 2008;60:57-61.
14. Henschke CI, McCauley DI, Yankelevitz DF, Naidich DP, McGuinness G, Miettinen OS, et al. Early Lung Cancer Action Project: overall design and findings from baseline screening. Lancet 1999;354:99-105. (Pubitemid 29313143)
15. Veronesi G, Bellomi M, Mulshine JL, Pelosi G, Scanagatta P, Paganelli G, et al. Lung cancer screening with low-dose computed tomography: a non-invasive diagnostic protocol for baseline lung nodules. Lung Cancer 2008;61:340-9.
16. Henschke CI, Yankelevitz DF, Libby DM, Pasmantier MW, Smith JP, Miettinen OS. Survival of patients with stage I lung cancer detected on CT screening. N Engl J Med 2006;355:1763-71.
17. Lazzeroni M, Guerrieri-Gonzaga A, Serrano D, Varricchio MC, Veronesi G, Radice D, et al. Budesonide versus placebo in high-risk population with screen-detected lung nodules: rationale, design and methodology. Contemp Clin Trials 2010;31:612-9.
18. Crausman RS, Lynch DA, Mortenson RL, King TE, Jr., Irvin CG, Hale VA, et al. Quantitative CT predicts the severity of physiologic dysfunction in patients with lymphangioleiomyomatosis. Chest 1996;109:131-7.
19. Paciocco G, Uslenghi E, Bianchi A, Mazzarella G, Roviaro GC, Vecchi G, et al. Diffuse cystic lung diseases: correlation between radiologic and functional status. Chest 2004;125:135-42.
20. American Thoracic Society. Standardization of spirometry, 1994 update. Am J Respir Crit Care Med 1995;152:1107-36.
21. American Thoracic Society. Single-breath carbon monoxide diffusing capacity (transfer factor). Recommendations for a standard technique-1995 update. Am J Respir Crit Care Med 1995;152:2185-98.
22. Therasse P, Arbuck SG, Eisenhauer EA, Wanders J, Kaplan RS, Rubinstein L, et al. New guidelines to evaluate the response to treatment in solid tumors. European Organization for Research and Treatment of Cancer, National Cancer Institute of the United States, National Cancer Institute of Canada. J Natl Cancer Inst 2000;92:205-16.
23. Bellomi M, Veronesi G, Rampinelli C, Ferretti S, De FE, Maisonneuve P. Evolution of lung nodules < or =5 mm detected with low-dose CT in asymptomatic smokers. Br J Radiol 2007;80:708-12.
24. Bach PB, Kattan MW, Thornquist MD, Kris MG, Tate RC, Barnett MJ, et al. Variations in lung cancer risk among smokers. J Natl Cancer Inst 2003;95:470-8.
25. Shapiro SS, Wilk MB. An analysis of variance test of normality. Biometrika 1965;52:591-9.
26. Wahidi MM, Govert JA, Goudar RK, Gould MK, McCrory DC. Evidence for the treatment of patients with pulmonary nodules: when is it lung cancer?: ACCP evidence-based clinical practice guidelines (2nd edition). Chest 2007;132 Suppl 3:S94-107.
27. Kerr KM. Pulmonary preinvasive neoplasia. J Clin Pathol 2001;54:257-71.
28. Kim HY, Shim YM, Lee KS, Han J, Yi CA, Kim YK. Persistent pulmonary nodular ground-glass opacity at thin-section CT: histopathologic comparisons. Radiology 2007;245:267-75.
29. Ohtsuka T, Watanabe K, Kaji M, Naruke T, Suemasu K. A clinicopathological study of resected pulmonary nodules with focal pure ground-glass opacity. Eur J Cardiothorac Surg 2006;30:160-3.
30. Lee HJ, Goo JM, Lee CH, Park CM, Kim KG, Park EA, et al. Predictive CT findings of malignancy in ground-glass nodules on thin-section chest CT: the effects on radiologist performance. Eur Radiol 2009;19:552-60.
31. Oda S, Awai K, Liu D, Nakaura T, Yanaga Y, Nomori H, et al. Ground-glass opacities on thin-section helical CT: differentiation between bronchioloalveolar carcinoma and atypical adenomatous hyperplasia. AJR Am J Roentgenol 2008;190:1363-8. (Pubitemid 351684900)
32. Hasegawa M, Sone S, Takashima S, Li F, Yang ZG, Maruyama Y, et al. Growth rate of small lung cancers detected on mass CT screening. Br J Radiol 2000;73:1252-9.
33. van den Berg RM, van Tinteren H, van Zandwijk N, Visser C, Pasic A, Kooi C, et al. The influence of fluticasone inhalation on markers of carcinogenesis in bronchial epithelium. Am J Respir Crit Care Med 2007;175:1061-5.
34. Barnes PJ. Molecular mechanisms and cellular effects of glucocorticosteroids. Immunol Allergy Clin North Am 2005;25:451-68.
35. Rasenack N, Steckel H, Muller BW. Micronization of anti-inflammatory drugs for pulmonary delivery by a controlled crystallization process. J Pharm Sci 2003;92:35-44.
36. El-Gendy N, Gorman EM, Munson EJ, Berkland C. Budesonide nanoparticle agglomerates as dry powder aerosols with rapid dissolution. J Pharm Sci 2009;98:2731-46.
37. Decramer M, Gosselink R, Rutten-Van MM, Buffels J, Van SO, Gevenois PA, et al. Assessment of progression of COPD: report of a workshop held in Leuven, 11-12 March 2004. Thorax 2005;60:335-42.
38. Sutherland ER, Allmers H, Ayas NT, Venn AJ, Martin RJ. Inhaled corticosteroids reduce the progression of airflow limitation in chronic obstructive pulmonary disease: a meta-analysis. Thorax 2003;58:937-41.